🧴 Dupilumab (Dupixent) IL-4/IL-13 Blockade Simulator

IL-4 and IL-13 Drive Chronic Type-2 Skin Inflammation

Placeholder: excess IL-4/IL-13 signaling sustains atopic dermatitis flares.

• IL-4 / IL-13: Key cytokines (Placeholder short note)
• Th2 cell: Driven cell type (Placeholder short note)
• IL-4Rα: Shared receptor (Placeholder short note)
• Atopic dermatitis: Clinical context (Placeholder short note)

Cytokine overdrive in Th2 disease

Placeholder paragraph describing IL-4/IL-13 overactivity in short form.

Dupilumab Binds IL-4Rα to Block Two Cytokines at Once

Placeholder: one antibody target intercepts both type I and type II receptor complexes.

• mAb: Drug class (Placeholder short note)
• IL-4Rα: Target (Placeholder short note)
• Type I & II: Receptors blocked (Placeholder short note)
• Subcutaneous: Dosing (Placeholder short note)

Mechanism of dual-pathway blockade

Placeholder paragraph describing dupilumab receptor binding briefly.

Interrupting Cytokine Drive Quiets Pruritus Circuits

Placeholder: sensory neuron sensitization falls as signaling drops.

• Pruritus: Symptom (Placeholder short note)
• Days-weeks: Onset of relief (Placeholder short note)
• JAK-STAT6: Pathway (Placeholder short note)
• NRS itch scale: Patient metric (Placeholder short note)

Neuroimmune itch signaling drop

Placeholder paragraph describing itch pathway suppression briefly.

Skin Lesions Resolve Progressively Across Weeks

Placeholder: erythema and lichenification decline with sustained therapy.

• 0-16 wk: Timeframe (Placeholder short note)
• Barrier repair: Tissue effect (Placeholder short note)
• Erythema fade: Visible sign (Placeholder short note)
• IGA / EASI: Assessment tool (Placeholder short note)

Progressive lesion clearance

Placeholder paragraph describing skin clearance over time briefly.

EASI Score Decline Quantifies Clinical Response

Placeholder: EASI-50/75/90 thresholds classify treatment response.

• EASI: Score used (Placeholder short note)
• 50/75/90: Response tiers (Placeholder short note)
• Week 16: Trial benchmark (Placeholder short note)
• Sustained control: Outcome (Placeholder short note)

Reading the EASI response curve

Placeholder paragraph describing EASI curve interpretation briefly.

Placeholder highlight: strong responders reach EASI-75 by week sixteen.